• Explore /
  • Poster
  • / DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.

DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.

Abstract Poster

Authors

null

Jee Sun Yoon

Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea

Jee Sun Yoon , Jin Won Kim , Ji-Won Kim , Tae-Yong Kim , Ah-Rong Nam , Ju-Hee Bang , Hye-Rim Seo , Jae-Min Kim , Kyoung Seok Oh , Peter G. Mortimer , Simon Smith , Do-Youn Oh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT04298021

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS4166)

DOI

10.1200/JCO.2021.39.15_suppl.TPS4166

Abstract #

TPS4166

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Vaibhav Sahai

First Author: YunJung Kim

First Author: James O'Bryan

First Author: Do-Youn Oh